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Abstract. – OBJECTIVE: Mammographic
breast density is a recognized risk factor for
breast cancer. The causes that lead to the pro-
liferation of the glandular breast tissue and,
therefore, to an increase of breast density are
still unclear. However, a treatment strategy to
reduce the mammary density may bring about
very relevant clinical outcomes in breast can-
cer prevention. 
Myo-inositol is a six-fold alcohol of cyclohexa-
ne, has already been proved to modulate differ-
ent pathways: inflammatory, metabolic, oxidative
and endocrine processes, in a wide array of hu-
man diseases, including cancer and the genesis
of mammary gland and breast diseases, like fi-
brosis, as well as metabolic and endocrine cues.
Similarly, boswellic acid and betaine (three-
methyl glycine) both inhibit inflammation and ex-
ert protective effects on breast physiology. 
Based on this scientific background, we hy-
pothesized that a combination including,
boswellic acid, betaine and myo-inositol would
be able to reduce breast density working on
different pathways.
PATIENTS AND METHODS: In this study,
seventy-six premenopausal women were ran-
domly assigned to the placebo and the experi-
mental drug arms (Eumastós®) for six months. 
RESULTS: After 6 months of treatment, statis-
tically significant difference between the two
groups was recorded on the breast density re-
duction (60% vs. 9%), using mammographic as
well as ultrasound examination. 
CONCLUSIONS: Preliminary data collected
here with support the starting assumptions,
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that the association comprising boswellic acid,
betaine and myo-inositol significantly reduces
mammary density, providing the first evidence
for a new and safe approach for the manage-
ment of mammographic density treatment.
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Introduction
Nowadays a high breast density is a recog-
nized risk factor for breast cancer. It is assessed
by mammography and expressed as the percent-
age of the breast area that is occupied by radio-
logically dense tissue. Several studies show that
women with a densest breast have a 4-6 fold in-
creased risk of breast cancer compared to women
with the least dense breast1-3. 
The mammographic density reflects variations
in breast tissue composition4. A number of studies
investigated the histopathological composition of
breast dense tissue correlating the results with
mammographies, but it is not yet completely clear
what mammographic density is biologically5,6.
However, it has become clear that stromal fibrosis
is a prominent feature in mammographically
dense breasts7-9 and an increased amount of epithe-
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lium and/or stroma are associated with more ex-
tensive percent mammographic density10. More-
over, dense breasts have higher level of collagen,
and altered expression of stromal proteins11,12. 
The exact mechanisms and the role of stroma in
causing cancer of epithelial cells have not yet been
completely elucidated, mammographic density is
associated with certain markers of epithelial
growth, and most definitely with breast stroma. In-
deed, epithelial and stromal cells, collagen, and fat,
the tissue components that contribute to variations
in mammographic density, are related to each other
in several ways. Epithelial and stromal cells com-
municate with each other by means of paracrine
growth factors13. Collagen is a product of stromal
fibroblasts, and adipocytes develop from the differ-
entiation of stromal preadipocytes14. Therefore,
disorders of the cross-talk among epithelial cells
and the surrounding stroma are deemed to partici-
pate in the aetiology of mammographic density
and this interaction is known to be important in
breast carcinogenesis15. Moreover, several studies
point out that the average percentage of mammo-
graphic density in the population decreases with
increasing age16-19 and increasing age is also asso-
ciated with a reduction in average amounts of stro-
mal and epithelial tissues in the breast that are re-
flected in the percent mammographic density20.
Percent mammographic density may, thus, re-
flect the cumulative exposure of breast stroma
and epithelium to hormones and growth factors
that stimulate cell division and changes in percent
mammographic density with age may reflect
changes in breast histology that are commonly re-
ferred to as involution. Furthermore, breast le-
sions including ductal carcinoma in situ, atypical
hyperplasia, hyperplasia without atypia and
columnar cell lesions are, to different degrees, as-
sociated with an increased risk of breast cancer
and extensive percent mammographic density is
associated with an increased risk of each of these
lesions6. The breast density appears to have both
a genetic component, but also a modifiable, non-
genetic component21,22. Even hormonal mecha-
nisms, the growth hormone-mediated release of
free fatty acids from adipocytes, and an increase
in the lipid substrate available for oxidative dam-
age, might be involved in the pathogenesis23.
Some studies show an increase of the breast
density in post-menopausal users of hormone re-
placement therapy (HRT) and for this reason the
antiestrogen tamoxifen is the favorite pharmaco-
logical treatment in the management of breast
density. Tamoxifen treatment in postmenopausal
women24,25 and treatment with a gonadotrophin-
releasing hormone agonist in premenopausal
women26, indeed, are associated with a reduction
in the rate of mammographic density. These
pharmacological treatments should be used only
in selected cases because of their known adverse
effects. As a matter of fact, breast density is still
an enigmatic condition: its causes are poorly un-
derstood and are likely to be multifactorial. Cur-
rent available therapies are inadequate and opti-
mal strategy is still warranted.
Myo-inositol is a six-fold alcohol of cyclo-
hexane, has been proved to modulate different
pathways: inflammatory27, metabolic28, oxida-
tive29 and endocrine processes in a wide array of
human diseases, including cancer30. Similarly,
boswellic acid and betaine (three-methyl
glycine)31,32 both inhibit inflammation and exert
protective effects on breast physiology33,34. 
Accordingly to these studies, in order to investi-
gate new and safe therapeutic strategies to reduce
breast density and to prevent the development of
breast cancer, we hypothesized that a combination
including myo-inositol, boswellic acid and betaine
(Eumastós®) would be beneficial in breast density
by displaying a pleiotropic effect on different
pathways, targeting inflammatory, metabolic and
endocrine processes altogether.
Patients and Methods
To investigate the therapeutic benefit of the ex-
perimental treatment we used a double-blind, ran-
domized, placebo controlled, parallel group de-
sign. Between February 2014 and November
2015, 76 premenopausal women, aged between
22-51 years and with high breast density were in-
cluded in the trial. Clinical and qualitative assess-
ment of breast density was obtained by twice dis-
tinct opinions carried out by expert radiologists
and was performed according to Boyd7, subdivid-
ing patients into four main categories: 1) almost
entirely fat, 2) scattered fibroglandular densities,
3) heterogeneously dense, 4) extremely dense.
Eligible criteria excluded: previous treatment
for the breast or hormonal treatments during the
last 4 months prior to the trial; patients affected
by breast cancer, suffering from bloody nipple
discharge, affected by pre-malignant lesions (car-
cinoma in situ), or other diseases were excluded.
Age, weight and clinical data were recorded
by an experienced surgeon for each patient and
are reported in Table I.
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Clinical data Placebo-group Experimental group
No. of patients 30 32
Age (mean, years) (SD) 39.1 (5.8) 38.7 (6.1)
Weight (mean, kg) (SD) 66.7 (5.6) 67.0 (3.4)
High breast density 22/30 (73%) 25/32 (78%)
Table I. Baseline characteristics of premenopausal randomised patients who concluded the study.
Component (mg) Placebo-control group IBAB
Myo-Inositol - 200
Boswellic acid - 50
Betaine - 175
Vitamin B6 2.1 2.1
Folic acid 0.3 0.3
Vitamin B2 2.1 2.1
Vitamin B12 0.003 0.003
N-acetylcysteine 100 100
Posology 1 capsule twice a day 1 capsule twice a day
Table II. Drug formula.
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means of Wald approximation. p < 0.05 was esti-
mated statistically significant.
Results
Taken as a whole the compliance among the
two groups was higher than expected, as the
treatment was discontinued only in a few cases
and for less than few days. Due to drop out, only
62 patients arrived at the last step of the study in-
volving breast density analysis.
Table III reports the results obtained pertain-
ing to the study groups (control and treatment). 
Breast density
As expected for young women, mammary tis-
sue density was increased in a relevant propor-
tion of cases. Within the control group, 22 out of
30 patients showed grade four breast density (ex-
tremely dense) and 25/32 women in the experi-
mental group were also affected by extremely
dense breast tissue.
At the end of the trial, whereas no appreciable
differences were found in the placebo group, an
unexpected and significant decrease in breast
density was recorded by mammography among
patients of the experimental arm (60%). There-
In order to ensure a correct balance between
groups, patients were randomized to treatment
using a minimization procedure39. 
In the first group, patients received oral cap-
sules (one capsule twice a day), containing a
combination of vitamins (B2, B6, folic acid)
and N-acetyl-cysteine; in the experimental arm,
patients received oral capsules (one capsule
twice a day), filled with the same control com-
position plus boswellic acid, betaine and myo-
inositol.
The control and the experimental formula (Eu-
mastós®) were kindly supplied from Lo.Li. Phar-
ma srl., Rome, Italy and were designed to have
an identical appearance (Table II).
The main outcome of the study was density re-
duction. Patients were requested not to change
their diet during participation in the trial. Mam-
mographic as well as ultrasound examination
were performed at the baseline and after the
treatment period (6 months).
Statistical Analysis
The few patients led us to adopt Fisher exact
test for assessing significance instead of Chi-
Square (cells with < 5 units). In addition to Fish-
er exact test significance, C.I: at 95% of the
Odds Ratio is reported, the CI was estimated by
High breast density (n) Breast density 
Pre-treatment Post-treatment reduction (%) p-value
Placebo group 22 20 9.1% ns
Experimental group 25 10 60% 0.001
Table III. Number of patients with high breast density and breast density reduction in the two groups. OR (95% Confidence
Interval) 2.46<15<118.3; p-values are estimated by Fisher exact test vs baseline.
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and safer treatment options prompted many clini-
cians to investigate different alternatives.
Several vitamins and antioxidants have been
evaluated as support in the management and pre-
vention of breast diseases. Among many formu-
lations, those including folate intake, vitamin B1,
B6, B12 and antioxidants, such as N-acetyl-
cysteine, have yielded some good results39-43 and
to date, vitamins supplementation is usually rec-
ommended by general practitioners.
By hypothesizing a synergy in between three
natural active compounds – boswellic acid, be-
taine and myo-inositol – sharing anti-inflamma-
tory and endocrine-modulating activities, we
have studied their combined effectiveness in a
pilot, randomised trial.
Preliminary data collected herewith support
the starting assumptions, that the association
comprising boswellic acid, betaine and myo-in-
ositol significantly reduces mammary density in
a relevant percentage of patients, without any rel-
evant side effects. Additionally, that formula
ameliorates other symptoms, like anxiety and
menstrual discomfort.
These effects are likely to be ascribed to the
pleiotropic mechanism of action exerted by
boswellia, betaine and myo-inositol on several
metabolic, inflammatory as well as endocrine
pathways. In particular the anti-inflammatory ac-
tivity of Boswellia is well known and this prop-
erty has been attributed to its ability in regulating
immune cytokine production and leukocyte infil-
tration44,45. Indeed the acetyl-keto-β-boswellic
acid (AKBA), a triterpenoid isolated from
boswellia, is able to act as 5-lipoxygenase in-
hibitor46,47. The boswellia has also been proposed
to provide antineoplastic through its anti-prolif-
erative and proapoptotic properties in different
human cancer cells48,49. Experimental models
showed that boswellic acid is able to inhibit cell
growth and to induce apoptosis in liver50, colon51
and prostate cancer52. Moreover, a study on
breast cancer cells lines point out the ability of
fore, breast density reduction was significantly
more marked in experimental arm (p < 0.001,
Table III).
It is worth nothing that among those patients
(15 responding patients out of 25 showing high
breast density), reduction in tissue compactness
was also associated to a significant pain reduc-
tion in almost all patients (13 out of 15, data not
shown).
Adverse effects
Overall no significant adverse effects were
recorded in both arms. Only one case in the ex-
perimental arm experienced transient mild diar-
rhoea.
Discussion
Data presented herein suggest that women
showing high breast density, experience a signif-
icant clinical benefit when treated with a bal-
anced composition including boswellic acid, be-
taine and myo-inositol (Eumastós®). A reduction
in breast density was achieved in a relevant por-
tion of patients enrolled in the experimental arm:
differences in response rate between control and
the experimental group showed to be very signif-
icant, indeed. Keeping in mind that increased
breast density is deemed to be a pivotal risk fac-
tor for breast cancer35 – being related to high tis-
sue stiffness and augmented remodelling rate –
reducing the mammary compactness by means of
a ‘simple’, natural remedy, may bring about very
relevant clinical outcomes. 
In order to prevent breast cancer, there is con-
siderable debate about the choice of the best
agent for initial management of mammographic
breast density36-38. Despite hormonal-based treat-
ment have provided consistent benefit in a large
proportion of patients, these drugs are difficult
easy to handle for prolonged period of time.
Consequently, the search for more manageable
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boswellia to modulate the expression of sig-
nalling molecules and cell cycle regulators such
as the caspase-3 in the MDA-MB-231 breast
cancer cells, and the phosphorylated levels of
Akt (Ser473) and Erk1/2 (Thr202/Tyr204) in
MCF7 cells. It is involved also in down-regula-
tion of the expression of cyclin D1, a crucial cell
cycle regulator involved in cancer development
and progression53. 
Myo-inositol showed to prevent pulmonary fi-
brosis after asbestos or inflammatory injury54, to
inhibit chronic colon inflammation, likely by
modulating the redox balance55. In addition,
myo-inositol and boswellia, may contrast inflam-
mation-induced fibrosis by modulating TGF-β
activity. TGF-β, in particular the TGF-β1 iso-
form, is a potent pro-fibrogenic agent inducing
collagen synthesis and regulating the balance be-
tween matrix-degrading metalloproteinases and
their inhibitors56,57, thus, resulting a prominent
factor in orchestrating the cross-talk among ep-
ithelial cells and their microenvironment58. Myo-
inositol significantly modulates the expression of
genes encoding TGF-βs and their receptors, and
by that way it exerts immune-regulatory effects
on colonic epithelium under inflammatory condi-
tions or during microbe-induced infection/in-
flammation in order to maintain the colonic mu-
cosa in a non-inflammatory state or to counteract
infection59,60. TGF-β down-regulation has been
observed in breast diseases61, such breast fibrosis
is usually recorded as an increase of breast densi-
ty during mammographic examination. Modula-
tion of these important biological activities by
myo-inositol and boswellia may improve the
breast density. In addition, myo-inositol exerts a
modulating activity on cell metabolism, by im-
proving glucose uptake and normalizing lipid
metabolism62. 
Therefore, it could be hypothesized that Myo-
inositol may improve the clinic-pathological fea-
tures of breast compactness by interfering with
tissue metabolism at local and systemic level. In
fact, as demonstrated by a compelling body of
scientific data, Myo-inositol improves metabolic
and hormonal pattern, being normally altered in
PCOS patients63,64. In fact, Myo-inositol restore
insulin sensitivity, counteract hyperandrogenism
and modulates oestrogen and FSH activity at
ovary level65,66. 
At last betaine, a nutrient involved in one-car-
bon metabolism and consequently in methylation
of DNA, influences gene stability, expression
and nucleotide synthesis and it intake could be
useful in the prevention of breast cancer develop-
ment67,68. Based on their mechanisms of action,
we speculate that the contribute of all these sub-
stances in the different biological pathways may
explain the positive effect on breast density.
Conclusions
Women showing high breast density, experi-
ence a significant clinical benefit when treated
with a balanced composition including boswellic
acid, betaine and myo-inositol. Undoubtedly, our
study suffers from limitations and our main find-
ings should be confirmed by a large survey, name-
ly by evaluating how long should last the clinical
response and how relevant could be the relapse
rate. Yet, data reported herewith preliminarly
demonstrated that the proposed treatment may en-
sure a high response rate without side-effects, thus
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